Replies to post #151800 on Biotech Values

[mcbio]

It is University of Oxford study.
Official Title: A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma
clinicaltrials.gov/ct2/show/NCT01256359?term=selumetinib&cond=melanoma&phase=1&rank=4

Aztra Zeneca coducted different study.
Official Title: A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
clinicaltrials.gov/ct2/show/NCT00936221?term=selumetinib&cond=melanoma&phase=1&rank=6

Different BRAF mutation status, different primary endpoints.

Good catch. I just assumed this was the AZN trial. So, we will see the effect of docetaxel with and without selumetinib in wild-type BRAF melanoma as opposed to dacarbazine with and without selumetinib in BRAF mutant melanoma.